Adjuvant treatment for renal cell carcinoma.
Despite significant advances in the diagnosis, staging and treatment of patients with renal cell carcinoma, recurrence rates following surgical resection of locally aggressive tumours remain high. In an effort to delay disease progression and improve survival, the concept of adjuvant therapy has been proposed. Optimal adjuvant therapy for surgically resected renal cell carcinoma remains to be defined and the evaluation of adjuvant therapies will require properly controlled and adequately powered randomised trials. Promising preliminary results have been seen with active immunotherapies and agents that target critical signalling pathways, and there are several Phase III trials of these novel treatment options that are underway. In addition, classification of patients into high- and low-risk subgroups on the basis of a prognosis profile will serve as a useful means to guide clinicians in improving the selection of patients who are likely to derive benefit from adjuvant therapy. This will lead to a future area of investigation, which will be the identification of patients within the target population that should respond to a given treatment. This review will discuss the role and current status of adjuvant therapies for renal cell carcinoma.
David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
John S
JS
Lam
Arie S
AS
Belldegrun
Robert A
RA
Figlin
D000277:Adjuvants, Pharmaceutic / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000532:radiotherapy / Q000628:therapy; D006801:Humans; D016233:Immunotherapy, Active; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000628:therapy
D000277:Adjuvants, Pharmaceutic; D000970:Antineoplastic Agents